Daniel Reyner - Concepedia

Author

Daniel Reyner

AstraZeneca (United States)

Also Known As

D Reyner, D. Reyner, DANIEL REYNER, Daniel Reyner

Publications

692

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United States)AstraZeneca (Sweden)University Medical Center Groningen AstraZeneca (Finland)University of Groningen

About

Daniel Reyner is an author at AstraZeneca (United States) specializing in medicine, pharmacology, and diabetes.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	225
2	Diabetes	2	2	204
3	Public Health	1	1	21
4	Environmental Health	1	1	21
5	Epidemiology	1	1	21

Daniel Reyner

Publications

442

Citations

H-Index

Page 1

	Year	Citations
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial Carol A. Pollock, Bergur V. Stefánsson, Daniel Reyner, The Lancet Diabetes & Endocrinology Metabolic SyndromeDiabetes ManagementRenal FunctionRenal DiseaseAlbuminuria-lowering Effect	2019	194
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study Paola Fioretto, Stefano Del Prato, John B. Buse, Diabetes Obesity and Metabolism	2018	182
TCE Meta-Analyses: Wartenberg et al.'s Response. Daniel Wartenberg, Daniel Reyner Environmental Health Perspectives Epidemiology Of CancerPathologyDaniel WartenbergResearch EthicsOncology	2000	21
Ensifentrine in COPD patients taking long-acting bronchodilators: A pooled post-hoc analysis of the ENHANCE-1/2 studies Mark T. Dransfield, Nathaniel Marchetti, Ravi Kalhan, Chronic Respiratory Disease	2025	13
Renal haemodynamic response to sodium‐glucose cotransporter‐2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials Annemarie B. van der Aart‐van der Beek, David Z.I. Cherney, Gozewijn D. Laverman, Diabetes Obesity and Metabolism	2021	11
Effect of ensifentrine on dyspnea in patients with moderate-to-severe chronic obstructive pulmonary disease: pooled analysis of the ENHANCE trials Donald A. Mahler, Surya P. Bhatt, Tara Rheault, Expert Review of Respiratory Medicine	2024	11
Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes Clifford J. Bailey, Stefano Del Prato, Cheryl Wei, Diabetes Obesity and Metabolism Metabolic SyndromeDiabetes ManagementSglt2 InhibitorDiabetes EpidemiologyCardiovascular Disease	2019	10

Page 1